With the advent of more successful chemotherapies, the number of cancer survivors continues to increase. Unfortunately, many of these patients will exhibit long-term sequelae from their treatments, including serious cognitive deficits that impair daily function. In this issue of Cell, Gibson et al. (2019) demonstrate that chemotherapy-related cognitive impairment is orchestrated by microglia.
Over the past several decades, we have witnessed dramatic improvements in cancer therapeutics, leading to longer overall patient survival. With increasing numbers of cancer survivors, there has been growing interest in defining and reducing the long-term side effects of cancer treatment. While the detrimental cognitive effects of cranial radiation (radiation therapy) have long been appreciated, more than 60% of patients treated with systemic chemotherapy develop cognitive disabilities that significantly impair activities of daily living, employment, and social relationships, which can last for years following the cessation of therapy. Specifically, chemotherapy-treated patients frequently report deficits in concentration, memory, multi-tasking, decision-making, learning, and language-colloquially referred to as ''chemobrain'' or ''chemofog.'' While these devastating consequences were first recognized in the late 1990s, the cellular and molecular etiologies have largely remained elusive. Several potential mechanisms have been proposed, including inhibition of hippocampal neurogenesis and direct neuronal injury, as well as secondary glial cell (microglia and astrocyte) activation, pro-inflammatory cytokine production, and myelin-producing (oligodendrocyte lineage) cell defects along white matter tracts ( Figure 1 ; left panel). In contrast to this neuron-centric model, the recent report by Monje and colleagues (Gibson et al., 2019 , this issue of Cell) provides compelling evidence that chemotherapy-related white matter pathology and cognitive impairment are caused by primary changes in glial cell (microglia and astrocyte) circuitry.
Using methotrexate treatment to study chemotherapy-related cognitive impair-ment, they demonstrate that persistent depletion of PDGFRa + /Olig2 + oligodendrocyte precursor cells (OPCs) in the subcortical white matter tracts is a hallmark feature of the disease in both humans and mice. This selective reduction of OPCs is consistent with prior studies, which found that OPCs are particularly sensitive to chemotherapeutic agents (Dietrich, et al., 2006) . Leveraging a new experimental murine model of methotrexate-induced neurological dysfunction, they next discovered that treatment reduces OPC proliferation and increases OPC differentiation, leading to long-term depletion (at least 6 months) of mature oligodendrocytes, preferentially in white matter regions. These abnormalities in OPC lineage dynamics result in a reduction in myelin sheath thickness and are associated with numerous behavioral deficits, including decreased forepaw swing speed, increased anxiety (attention system dysfunction), and persistent cognitive defects. Surprisingly, the observed OPC lineage defects following systemic chemotherapy reflect essential contributions from the local brain microenvironment, in that naive OPCs exhibit altered oligodendrocyte maturation following transplantation into the brains of methotrexate-treated mice. This stromal effect was mediated by resident brain monocytes (microglia): pharmacologic depletion of microglia corrected the methotrexate-induced reductions in oligodendrocyte density and myelin sheath thickness, as well as the associated cognitive and behavioral deficits. While the exact etiologic mechanisms remain to be completely elucidated, this reprogramming of microglia results in the production of pro-inflammatory cytokines and the activation of astrocytes (''reactive astrocytes''), which, through the elaboration of additional paracrine factors, culminates in disturbed OPC maturation. Collectively, these novel findings support a model in which chemotherapy triggers a cascade of cellular and molecular events, beginning with microglia, to generate reactive astrocytes and disturb OPC dynamics, myelin microarchitecture, and mouse behavior (Figure 1, right panel) .
The exciting insights described in this report expand the role of glia in influencing central nervous system pathobiology. First, the finding that microglia act to initiate the process of oligodendrocyte-induced neuronal dysfunction in chemotherapy-related cognitive impairment builds upon emerging evidence demonstrating that these brain macrophages are not only critical sensors of local brain health and disease, but are also cellular effectors that create neuronal injury and enact changes in glial cell function. In this regard, microglia can be reprogrammed to produce inflammatory cytokines that injure neurons in experimental models of low-grade brain tumors (Toonen, et al., 2017) , activate astrocytes to damage neurons (Liddelow, et al., 2017) , and inappropriately prune synaptic processes and engulf neuronal debris in the setting of Alzheimer's disease (Hong, et al., 2016) . Additionally, microglia can function as stromal drivers of brain tumor development and progression through the elaboration of instructive chemokines and growth factors, suggesting adjuvant brain tumor therapeutic strategies that target these monocytes and their paracrine effector proteins.
Second, the discovery that microglial activation enacts a cascade of cellular and molecular events involved in the brain response to chemotherapy parallels prior findings that similarly implicated microglia in the genesis of radiation therapyinduced cognitive impairments. In these studies, cranial radiation therapy was associated with a selective reduction in the production of new neurons from neural progenitor cells in the rodent hippo-campus, and impairments in learning and memory. Importantly, these deficits in neurogenesis resulted from radiationinduced microglia activation and the production of pro-inflammatory cytokines (e.g., interleukin-6) (Monje et al., 2003) . While other cytokines likely also contribute to this microglia-induced defect in neurogenesis, together with the current study, these data support a role for immunomodulatory approaches that might mitigate against cancer treatmentassociated damage to the brain (Feng, et al., 2018) .
Third, the finding that chemotherapy results in the establishment of a new function state for astrocytes and microglia strengthens the concept that glia are In the traditional neuron-centric model (left), chemotherapy acts primarily on neurons, eliciting a cascade of events that culminate in the activation of microglia and astrocytes, as well as disrupting the normal homeostatic relationship between myelinating cells (oligodendrocytes) and oligodendrocyte precursor cells (OPCs). Activation of microglia and astrocytes, in turn, leads to inappropriate synaptic pruning and the release of neurotoxins (e.g., interleukin-1b), while disturbances in oligodendrocyte-axon interactions cause impaired axonal maintenance, which collectively damage neurons and result in impaired neuronal function and mouse behavior. In the model proposed by Gibson and colleagues (right) , chemotherapy has its primary effect on microglia, which act to orchestrate a series of cellular and molecular events through paracrine mediators that activate astrocytes, disturb OPC dynamics and oligodendrocyte function, and ultimately result in impaired axonal maintenance, neuronal function, and mouse behavior.
highly dynamic cell populations whose biology is largely dictated by the local microenvironment (context dependency). For this reason, it might be more meaningful to classify glial cells by the specific molecular (e.g., transcriptional profiles) and functional (e.g., phagocytosis, inflammatory cytokine production) properties that constitute their respective contextresponsive states. In this regard, recent reports have revealed that specific central nervous system environments (reflecting different developmental stages and diseases) actively sculpt microglia identity (Bennett, et al., 2018) , as well as dictate their function in neural circuit maintenance (Schafer et al., 2012) and myelination (Bennett & Barres, 2017) . The use of these context-dependent classifications might be useful in defining the specific contributions of different glial cell populations to disease pathogenesis, and for the design of stroma-directed therapies that aim to treat disorders of the brain characterized by microglia infiltration and reactive astrocytosis.
Future investigations that aim to distinguish microglia from infiltrating peripheral macrophages and better define the transcriptional and epigenetic programs that establish these specialized microglial functional states will likely provide a more complete picture of the complex and varied roles that glial cells play in both health and in the setting of brain disease.
Regulation of protein-DNA binding specificity occurs through myriad mechanisms. Boudet et al. discover yet a new form of specificity through allosteric regulation, an ATP-induced structural switch that mediates specific DNA recognition in an archaeoeukaryotic primase.
Gene expression and its regulation depend on sequence-specific recognition by DNA-binding proteins. Direct protein-DNA interactions and indirect allosteric conformational changes, typically induced by effector proteins (Siggers et al., 2011; Siggers and Gordâ n, 2014), subtend sequence-specific interactions, many characterized in structural detail. Allosteric regulation of DNA-binding proteins by smaller cofactors such as ATP has also long been observed to enhance or repress transcription factor binding or improve polymerase fidelity (Frick et al., 1999) ; however, the specific or nonspecific character of a DNA-protein recognition event has never been shown before to be allosterically controlled. Through a remarkable structural tour de force, Boudet et al. uncover an ATP-induced allosteric switch that
